Instilling AI and scaling Dupixent: two pillars of Hudson’s strategy at Sanofi

Two factors may come to define Paul Hudson’s tenure as CEO of Sanofi: Dupixent and AI. The former, he inherited in its post-approval infancy, and it’s been his to scale. The second he’s bringing in, and the opportunity, and Hudson’s intention, is to use the technology to revamp the company, soup to nuts.

In a conversation with BioCentury, Hudson outlined why he thinks he’s only scratched the surface with Dupixent dupilumab, and why AI may be a path not only to efficiency and better margins, but to rebooting company culture by taking the internal politics and careerism out of behaviors. ...